The abstract is read at the publisher; the summary is JClub's.
Adding oxaliplatin to S-1 after D2 gastrectomy improves overall survival in stage II–III gastric or GEJ adenocarcinoma, with HR 0.74 and 5-year OS 70.9% vs 62.9%.
- Why it matters: Standard adjuvant chemotherapy after D2 surgery is established, but the added benefit of oxaliplatin to S-1 needed confirmation in a large randomized phase 3 setting.
- What they did: In the multicenter CAPITAL phase 3 trial, 724 patients with resected pathological stage II–III gastric or GEJ adenocarcinoma were randomized 1:1 to SOX (n=362) or S-1 (n=362), with overall survival as the primary endpoint.
- The result: Median follow-up was 74.0 months; 5-year disease-free survival was 66.2% with SOX vs 55.6% with S-1 (HR 0.76), while grade 3–4 treatment-related adverse events were higher (25% vs 13%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.